Metsera

Metsera Long-term Debt

Delisted

The Long-Term Debt of Metsera (MTSR) as of Nov 4, 2026 is 15.18 M USD.

Long-term Debt

15.18 MUSD

Last updated:

Long-Term Debt of Metsera is 2022 15.18 M USD. Long-Term Debt of Metsera was 2021 - USD. It decreases by % lower compared to the previous year.

The Metsera Long-term Debt history

The Metsera Long-term Debt history
YEARLong-term DebtYoY
15.18 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Metsera Stock analysis

What does Metsera do? Metsera Inc. is a clinical stage biopharmaceutical company based in New York City, operating in the Health Care sector with a focus on Biotechnology. The company develops next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for treating obesity and related conditions. Utilizing its proprietary MINT peptide library, HALO half-life extension platform, and MOMENTUM oral delivery system, Metsera has a pipeline including MET-097i, MET-233i, and MET-224o, targeting various obesity treatments with differentiated approaches. Listed on 31 January 2025, the company employs 82 staff. Metsera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Metsera stock

Long-Term Debt of Metsera is 15.18 M USD in 2022.

On Eulerpool you can find the complete historical development of Long-Term Debt Metsera since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Metsera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Metsera

All Key Metrics — Metsera